312 related articles for article (PubMed ID: 20693850)
1. Artificial antigen-presenting cells for use in adoptive immunotherapy.
Turtle CJ; Riddell SR
Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850
[TBL] [Abstract][Full Text] [Related]
2. Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy.
Hasan AN; Selvakumar A; O'Reilly RJ
Adv Genet Eng; 2015; 4(3):. PubMed ID: 29644163
[TBL] [Abstract][Full Text] [Related]
3. Artificial Antigen-Presenting Cells for Immunotherapies.
Siefert AL; Fahmy TM; Kim D
Methods Mol Biol; 2017; 1530():343-353. PubMed ID: 28150213
[TBL] [Abstract][Full Text] [Related]
4. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.
Eggermont LJ; Paulis LE; Tel J; Figdor CG
Trends Biotechnol; 2014 Sep; 32(9):456-65. PubMed ID: 24998519
[TBL] [Abstract][Full Text] [Related]
5. Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
Butler MO; Hirano N
Immunol Rev; 2014 Jan; 257(1):191-209. PubMed ID: 24329798
[TBL] [Abstract][Full Text] [Related]
6. Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.
Sun W; Subrahmanyam PB; East JE; Webb TJ
J Interferon Cytokine Res; 2012 Nov; 32(11):505-16. PubMed ID: 23050947
[TBL] [Abstract][Full Text] [Related]
7. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Rhodes KR; Green JJ
Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
[TBL] [Abstract][Full Text] [Related]
9. Potential advantages of CD1-restricted T cell immunotherapy in cancer.
Consonni M; Dellabona P; Casorati G
Mol Immunol; 2018 Nov; 103():200-208. PubMed ID: 30308433
[TBL] [Abstract][Full Text] [Related]
10. HLA-Class II Artificial Antigen Presenting Cells in CD4
Couture A; Garnier A; Docagne F; Boyer O; Vivien D; Le-Mauff B; Latouche JB; Toutirais O
Front Immunol; 2019; 10():1081. PubMed ID: 31156634
[TBL] [Abstract][Full Text] [Related]
11. Harnessing human plasmacytoid dendritic cells as professional APCs.
Tel J; van der Leun AM; Figdor CG; Torensma R; de Vries IJ
Cancer Immunol Immunother; 2012 Aug; 61(8):1279-88. PubMed ID: 22294456
[TBL] [Abstract][Full Text] [Related]
12. Technological advances in adoptive immunotherapy.
Oelke M; Krueger C; Schneck JP
Drugs Today (Barc); 2005 Jan; 41(1):13-21. PubMed ID: 15753966
[TBL] [Abstract][Full Text] [Related]
13. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.
Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B
Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890
[TBL] [Abstract][Full Text] [Related]
14. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
15. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
[TBL] [Abstract][Full Text] [Related]
16. Quality and quantity: new strategies to improve immunotherapy of cancer.
Krueger C; Schneck JP; Oelke M
Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
[TBL] [Abstract][Full Text] [Related]
17. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
Paulos CM; Suhoski MM; Plesa G; Jiang T; Basu S; Golovina TN; Jiang S; Aqui NA; Powell DJ; Levine BL; Carroll RG; Riley JL; June CH
Immunol Res; 2008; 42(1-3):182-96. PubMed ID: 18949448
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunotherapy of cancer.
Yang JC
Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
[TBL] [Abstract][Full Text] [Related]
20. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
